2016 Section 5 Green Book

24. Zivadinov R, Zorzon M, Monti Bragadin L, Pagliaro G, Cazzato G. Olfactory loss in multiple sclerosis. J Neurol Sci . 1999;168(2):127-130. 25. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dys- function in early stage treated and untreated idiopathic Parkinson’s disease. J Neu- rol Neurosurg Psychiatry . 1992;55(2):138-142. 26. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord . 2001;16(1):41-46. 27. Hummel T, Jahnke U, Sommer U, Reichmann H, Mu¨ller A. Olfactory function in patients with idiopathic Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm . 2005;112(5):669-676. 28. Liberini P, Parola S, Spano PF, Antonini L. Olfaction in Parkinson’s disease: meth- ods of assessment and clinical relevance. J Neurol . 2000;247(2):88-96. 29. Kesslak JP, Cotman CW, Chui HC, et al. Olfactory tests as possible probes for detecting and monitoring Alzheimer’s disease. Neurobiol Aging . 1988;9(4): 399-403. 30. Serby MJ. Olfactory deficit in Alzheimer’s disease? Am J Psychiatry . 2001;158(9): 1534-1535. 31. O¨ zben T, Chevion M, eds. Frontiers in Neurodegenerative Disorders and Aging: Fundamental Aspects, Clinical Perspectives and New Insights. Vol 358. Amster- dam, the Netherlands: IOS Press; 2004. NATO Science Series, I: Life and Behav- ioral Sciences. 32. Warner MD, Peabody CA, Flattery JJ, Tinklenberg JR. Olfactory deficits and Alz- heimer’s disease. Biol Psychiatry . 1986;21(1):116-118. 33. Moberg PJ, Doty RL. Olfactory function in Huntington’s disease patients and at- risk offspring. Int J Neurosci . 1997;89(1-2):133-139. 34. Henkin RI, Velicu I, Papathanassiu A. cAMP and cGMP in human parotid saliva: relationships to taste and smell dysfunction, gender, and age. Am J Med Sci . 2007;334(6):431-440. 35. Henkin RI, Velicu I. Decreased parotid salivary cyclic nucleotides related to smell loss severity in patients with taste and smell dysfunction. Metabolism . 2009; 58(12):1717-1723. 36. Henkin RI, Velicu I. cAMP and cGMP in nasal mucus: relationships to taste and smell dysfunction, gender and age. Clin Invest Med . 2008;31(2):E71-E77. http: //cimonline.ca/index.php/cim/article/view/3366. Accessed March 10, 2011. 37. Henkin RI, Velicu I. cAMP and cGMP in nasal mucus related to severity of smell loss in patients with smell dysfunction. Clin Invest Med . 2008;31(2):E78-E84. 38. Henkin RI, Velicu I. Etiological relationships of parotid saliva cyclic nucleotides in patients with taste and smell dysfunction. Arch Oral Biol . 2012;57(6):670- 677. http://cimonline.ca/index.php/cim/article/view/3367. Accessed January 20, 2012. 39. Henkin RI, Velicu I. Aetiological relationships of nasal mucus cyclic nucleotides in patients with taste and smell dysfunction. J Clin Pathol . 2012;65(5):447- 451. 40. Henkin RI, Velicu I, Schmidt L. An open-label controlled trial of theophylline for treatment of patients with hyposmia. Am J Med Sci . 2009;337(6):396-406. 41. Gudziol V, Hummel T. Effects of pentoxifylline on olfactory sensitivity: a post- marketing surveillance study. Arch Otolaryngol Head Neck Surg . 2009;135 (3):291-295. 42. Henkin RI, Velicu I, Schmidt L. Relative resistance to oral theophylline treatment in patients with hyposmia manifested by decreased secretion of nasal mucus cyclic nucleotides. Am J Med Sci . 2011;341(1):17-22. 43. Weinberger M. Theophylline for treatment of asthma. J Pediatr . 1978;92(1):1-7. 44. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J . 1994;7(3):579-591. 45. Henkin RI. Comparative monitoring of oral theophylline treatment in blood se- rum, saliva, and nasal mucus. Ther Drug Monit . 2012;34(2):217-221. 46. Church JA, Bauer H, Bellanti JA, Satterly RA, Henkin RI. Hyposmia associated with atopy. Ann Allergy . 1978;40(2):105-109. 47. Henkin RI, Larson AL, Powell RD. Hypogeusia, dysgeusia, hyposmia, and dys- osmia following influenza-like infection. Ann Otol Rhinol Laryngol . 1975;84 (5, pt 1):672-682. 48. Schechter PJ, Henkin RI. Abnormalities of taste and smell after head trauma. J Neurol Neurosurg Psychiatry . 1974;37(7):802-810. 49. Henkin RI, Levy LM. Functional MRI of congenital hyposmia: brain activation to odors and imagination of odors and tastes. J Comput Assist Tomogr . 2002; 26(1):39-61.

50. Henkin RI. Taste in man. In: Harrison D, Hinchcliffe R, eds. Scientific Founda- tions of Otolaryngology. London, England: Wm Heinemann Medical Books Ltd; 1976:469-483. 51. Henkin RI, Schecter PJ, Friedewald WT, Demets DL, Raff MS. A double blind study of the effects of zinc sulfate on taste and smell dysfunction. Am J Med Sci . 1976; 272(3):285-299. 52. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res . 1992;9(1):1-9. 53. Al Suleimani YM, Walker MJ. Allergic rhinitis and its pharmacology. Pharmacol Ther . 2007;114(3):233-260. 54. Watelet JB, Gillard M, Benedetti MS, Lelièvre B, Diquet B. Therapeutic manage- ment of allergic diseases. Drug Metab Rev . 2009;41(3):301-343. 55. Djukanovic´ R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J . 1995;8(5):831-833. 56. Thorne RG, Emory CR, Ala TA, Frey WH II. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res . 1995;692(1-2):278-282. 57. Putcha L, Tietze KJ, Bourne DW, Parise CM, Hunter RP, Cintro´n NM. Bioavail- ability of intranasal scopolamine in normal subjects. J Pharm Sci . 1996;85 (8):899-902. 58. Kubek MJ, Ringel I, Domb AJ. Issues in intranasal neuropeptide uptake. In: Ko- biler D, Lustig S, Shapiro S, eds. Blood-Brain Barrier: Drug Delivery and Brain Pathology. New York, NY: Springer; 2001:331. 59. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol . 2004;56(1):3-17. 60. Dorman DC, Brenneman KA, McElveen AM, Lynch SE, Roberts KC, Wong BA. Olfactory transport: a direct route of delivery of inhaled manganese phosphate to the rat brain. J Toxicol Environ Health A . 2002;65(20):1493-1511. 61. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology . 1994;135(5):1753-1761. 62. Kastin AJ, PanW. Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity? Endocrinology . 2006;147(5):2086-2087. 63. Dahlin M, Bjo¨rk E. Nasal absorption of (S)-UH-301 and its transport into the ce- rebrospinal fluid of rats. Int J Pharm . 2000;195(1-2):197-205. 64. Banks WA. The source of cerebral insulin. Eur J Pharmacol . 2004;490(1-3):5-12. 65. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem . 1985;44(6):1771-1778. 66. Henkin RI. Intranasal insulin: from nose to brain. Nutrition . 2010;26(6):624-633. 67. Dahlin M, Jansson B, Bjo¨rk E. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci . 2001;14(1):75-80. 68. Dahlin M, Bergman U, Jansson B, Bjo¨rk E, Brittebo E. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res . 2000; 17(6):737-742. 69. Evans J, Hastings L. Accumulation of Cd(II) in the CNS depending on the route of administration: intraperitoneal, intratracheal, or intranasal. FundamAppl Toxicol . 1992;19(2):275-278. 70. Chow HS, Chen Z, Matsuura GT. Direct transport of cocaine from the nasal cav- ity to the brain following intranasal cocaine administration in rats. J Pharm Sci . 1999;88(8):754-758. 71. Henkin RI. Intranasal delivery to the brain. Nat Biotechnol . 2011;29(6):480. doi: 10.1038/nbt.1866. 72. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med . 1995;332(13):868- 875. 73. Bush A. Practice imperfect: treatment for wheezing in preschoolers. N Engl J Med . 2009;360(4):409-410. 74. Syrett N, Abu-Shakra S, Yates R. Zolmitriptan nasal spray: advances in migraine treatment. Neurology . 2003;61(8)(suppl 4):S27-S30. 75. Zheng YQ, Wei W, Shen YX, Dai M, Liu LH. Oral and nasal administration of chicken type II collagen suppresses adjuvant arthritis in rats with intestinal lesions in- duced by meloxicam. World J Gastroenterol . 2004;10(21):3165-3170. 76. Mattsson LA, Christiansen C, Colau JC, et al. Clinical equivalence of intranasal and oral 17 -estradiol for postmenopausal symptoms. Am J Obstet Gynecol . 2000;182(3):545-552. 77. Ziai F, Walter R, Rosenthal IM. Treatment of central diabetes insipidus in adults and children with desmopressin. Arch Intern Med . 1978;138(9):1382-1385. 78. Fjellestad-Paulsen A, Wille S, Harris AS. Comparison of intranasal and oral des- mopressin for nocturnal enuresis. Arch Dis Child . 1987;62(7):674-677.

ARCH OTOLARYNGOL HEAD NECK SURG/VOL 138 (NO. 11), NOV 2012 WWW.ARCHOTO.COM

7